Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026

Key Takeaways Lilly's Mounjaro and Zepbound drove $36.5B in 2025 sales, fueling strong cardiometabolic growth.Novo Nordisk expects 2026 sales and operating profit to decline amid competition and pricing pressure.LLY shares rose 17.4% in a year, while NVO plunged 56.4%.Novo Nordisk (NVO) and Eli Lilly (LLY) lead the diabetes and obesity market, driven by blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk m ...